These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 23317530)

  • 1. ANCHOR trial conclusions regarding the effects of pure eicosapentaenoic acid on low-density lipoprotein cholesterol.
    Baum SJ
    Am J Cardiol; 2013 Feb; 111(3):454-5. PubMed ID: 23317530
    [No Abstract]   [Full Text] [Related]  

  • 2. Authors' reply.
    Ballantyne CM; Bays HE; Braeckman RA; Soni PN
    Am J Cardiol; 2013 Feb; 111(3):455-6. PubMed ID: 23317532
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
    Ballantyne CM; Bays HE; Kastelein JJ; Stein E; Isaacsohn JL; Braeckman RA; Soni PN
    Am J Cardiol; 2012 Oct; 110(7):984-92. PubMed ID: 22819432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
    Brinton EA; Ballantyne CM; Guyton JR; Philip S; Doyle RT; Juliano RA; Mosca L
    J Womens Health (Larchmt); 2018 Sep; 27(9):1170-1176. PubMed ID: 29583081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
    Ballantyne CM; Bays HE; Philip S; Doyle RT; Braeckman RA; Stirtan WG; Soni PN; Juliano RA
    Atherosclerosis; 2016 Oct; 253():81-87. PubMed ID: 27596132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-density lipoprotein cholesterol and triglycerides in the statin era: a pending issue?
    Paillard F
    Arch Cardiovasc Dis; 2009 Mar; 102(3):165-7. PubMed ID: 19375669
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical trials of eicosapentaenoic acid (EPA) prescription products for the treatment of hypertriglyceridemia.
    Doggrell SA
    Expert Opin Pharmacother; 2019 Jul; 20(10):1221-1225. PubMed ID: 31038369
    [No Abstract]   [Full Text] [Related]  

  • 8. Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT.
    Singh N; Bhatt DL; Miller M; Steg PG; Brinton EA; Jacobson TA; Jiao L; Tardif JC; Mason RP; Ballantyne CM;
    J Am Coll Cardiol; 2022 Jan; 79(2):220-222. PubMed ID: 35027114
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.
    Dunbar RL; Nicholls SJ; Maki KC; Roth EM; Orloff DG; Curcio D; Johnson J; Kling D; Davidson MH
    Lipids Health Dis; 2015 Sep; 14():98. PubMed ID: 26328624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Icosapent ethyl for hypertriglyceridaemia and atherosclerosis: greater RESPECT for increased therapeutic use.
    Gaba P; Bhatt DL; Boden WE
    Eur Heart J; 2024 Feb; 45(6):439-442. PubMed ID: 37889071
    [No Abstract]   [Full Text] [Related]  

  • 11. Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT.
    Gaba P; Bhatt DL; Mason RP; Miller M; Verma S; Steg PG; Boden WE;
    J Clin Lipidol; 2022; 16(4):389-402. PubMed ID: 35773147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction.
    Boden WE; Baum S; Toth PP; Fazio S; Bhatt DL
    Future Cardiol; 2021 Jan; 17(1):155-174. PubMed ID: 32959713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials).
    Mosca L; Ballantyne CM; Bays HE; Guyton JR; Philip S; Doyle RT; Juliano RA
    Am J Cardiol; 2017 Feb; 119(3):397-403. PubMed ID: 27939227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).
    Bays HE; Ballantyne CM; Kastelein JJ; Isaacsohn JL; Braeckman RA; Soni PN
    Am J Cardiol; 2011 Sep; 108(5):682-90. PubMed ID: 21683321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing hypertriglyceridemia: What can we learn from cardiovascular outcomes trials?
    Copple T; Ciffone NA
    Nurse Pract; 2017 Dec; 42 Suppl 12():3-9. PubMed ID: 29176336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the clinical benefits of lipid-disorder drugs.
    Hiatt WR; Smith RJ
    N Engl J Med; 2014 Jan; 370(5):396-9. PubMed ID: 24476429
    [No Abstract]   [Full Text] [Related]  

  • 17. Drugs for hypertriglyceridemia.
    Med Lett Drugs Ther; 2013 Mar; 55(1411):17-9. PubMed ID: 23467119
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of MAT9001 containing eicosapentaenoic acid and docosapentaenoic acid, compared to eicosapentaenoic acid ethyl esters, on triglycerides, lipoprotein cholesterol, and related variables.
    Maki KC; Bobotas G; Dicklin MR; Huebner M; Keane WF
    J Clin Lipidol; 2017; 11(1):102-109. PubMed ID: 28391875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new pure ω-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trial.
    Jacobson TA
    Expert Rev Cardiovasc Ther; 2012 Jun; 10(6):687-95. PubMed ID: 22894624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl.
    Steg PG; Bhatt DL
    Eur Heart J; 2021 Dec; 42(47):4865-4866. PubMed ID: 34734264
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.